PT  - JOURNAL ARTICLE
AU  - TAKEHIRO OTOSHI
AU  - TATSUYA NAGANO
AU  - JONGUK PARK
AU  - KOJI HOSOMI
AU  - TOMOYA YAMASHITA
AU  - MOTOKO TACHIHARA
AU  - TOKIKO TABATA
AU  - REINA SEKIYA
AU  - YUGO TANAKA
AU  - KAZUYUKI KOBAYASHI
AU  - KENJI MIZUGUCHI
AU  - TOMOO ITOH
AU  - YOSHIMASA MANIWA
AU  - JUN KUNISAWA
AU  - YOSHIHIRO NISHIMURA
TI  - The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma
AID  - 10.21873/anticanres.15633
DP  - 2022 Mar 01
TA  - Anticancer Research
PG  - 1589--1598
VI  - 42
IP  - 3
4099  - http://ar.iiarjournals.org/content/42/3/1589.short
4100  - http://ar.iiarjournals.org/content/42/3/1589.full
SO  - Anticancer Res2022 Mar 01; 42
AB  - Background/Aim: The gut microbiome plays an important role in the immune system and has attracted attention as a biomarker of several diseases, including cancer. In this study, we examined the relationship between the gut microbiome and lung cancer progression. Patients and Methods: Female never-smokers diagnosed with lung adenocarcinoma were consecutively enrolled between May 2018 and August 2019, and fecal samples were collected. Principal coordinate analyses were performed using Bray-Curtis distance matrices to investigate the effects of clinical variables (age, body mass index, Tumor-Node-Metastasis stage, T category, N category, M category, primary tumor size, performance status, and EGFR mutation status) on the gut microbial community. Results: A total of 37 patients were enrolled. T category and primary tumor size were significantly correlated with the gut microbial community (p=0.018 and 0.041, respectively). Conclusion: This study identified the gut microbiome as a promising biomarker of lung cancer progression.